YU79802A - Formulation having mobilizing activity - Google Patents

Formulation having mobilizing activity

Info

Publication number
YU79802A
YU79802A YU79802A YUP79802A YU79802A YU 79802 A YU79802 A YU 79802A YU 79802 A YU79802 A YU 79802A YU P79802 A YUP79802 A YU P79802A YU 79802 A YU79802 A YU 79802A
Authority
YU
Yugoslavia
Prior art keywords
formulation
mobilizing activity
haematopoietic
mobilizing
activity
Prior art date
Application number
YU79802A
Other languages
Serbo-Croatian (sh)
Inventor
Laura Ferro
Roberto Porta
Massimo Lacobelli
Massimo Alessandro Gianni
Carlo Carmelo Stella
Original Assignee
Gentium Spa.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gentium Spa. filed Critical Gentium Spa.
Publication of YU79802A publication Critical patent/YU79802A/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A description is given of a method of increasing the amount of stem cells and progenitor cells in the peripheral blood of a mammal; the method is characterised by the administration of defibrotide in combination or in temporal proximity with at least one haematopoietic factor, (preferably G-CSF) having the capacity to mobilise haematopoietic progenitora.
YU79802A 2000-04-18 2001-04-10 Formulation having mobilizing activity YU79802A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00083029 2000-04-18

Publications (1)

Publication Number Publication Date
YU79802A true YU79802A (en) 2005-11-28

Family

ID=47740687

Family Applications (1)

Application Number Title Priority Date Filing Date
YU79802A YU79802A (en) 2000-04-18 2001-04-10 Formulation having mobilizing activity

Country Status (1)

Country Link
YU (1) YU79802A (en)

Similar Documents

Publication Publication Date Title
MY125539A (en) Generation of therapeutic microfoams
MY122383A (en) Cyclic boroproline compounds
TW200505901A (en) Muscarinic agonists
MXPA02002895A (en) Topical treatment of streptococcal infections.
GB9807639D0 (en) Anti-inflammatory agents
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
GB9415167D0 (en) Improvements relating to cancer therapy
MXPA02003809A (en) Disposable absorbent article with containment structure.
MXPA02002681A (en) Use of g(a)-linolenic acid metabolites in the manufacture of a medicament for the treatment or prevention of cancer.
MXPA02010346A (en) Formulation having mobilising activity.
AU2001269688A1 (en) Combination containing an antifolate and methylmalonic acid lowering agent
HUS1900041I1 (en) Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation
WO2001089536A3 (en) Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
IL158155A0 (en) Use of erythropoietin to ameliorate chemotherapy-induced toxicity in vivo
WO2002026245A3 (en) Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
HK1029932A1 (en) Use of mirtazapine for the manufacture of a medicament for treating sleep apneas.
MD990258A (en) Method of treatment of the acute viral hepatitis B
IL148777A (en) Mirtazapine dosage unit for peroral administration
YU79802A (en) Formulation having mobilizing activity
EP1123100A4 (en) Improving memory by the administration of delta 5-androstene-3 beta-ol-7,17-dione and 3 beta esters thereof
NZ506406A (en) Compositions comprising Mycobacterium phlei DNA and methods for its use in the treatment of bladder cancer
EP0340933A3 (en) Heparin-containing formulations
Kim et al. Synergistic Cooperation Between Human Chorionic Gonadotropin and rIFN-Υ for Induction of Nitric Oxide Synthesis
Lee et al. Acute Oral, Intramuscular and Intravenous Toxicity Studies of Recombinant Interferon-alpha2a in Sprague-Dawley Rats
WO2002076405A3 (en) Compositions and methods of treatment of ulcerating diseases, burns, and related conditions